Quantitative impact of human immunodeficiency virus infection on tuberculosis dynamics

American Journal of Respiratory and Critical Care Medicine

Volumn 176, Issue 9, 2007, Pages 936-944

  DeRiemer, Kathryn ^a   Kawamura, L Masae ^b,c   Hopewell, Philip C ^c,d   Daley, Charles L ^d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^c Francis J Curry National Tuberculosis Center   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Genotyping; HIV infection; Transmission; Tuberculosis

Indexed keywords

ADULT; ARTICLE; ATTRIBUTABLE RISK; COMORBIDITY; EPIDEMIC; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SUPERINFECTION; TUBERCULOSIS; UNITED STATES;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; CLUSTER ANALYSIS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SAN FRANCISCO; TIME FACTORS; TUBERCULOSIS;

EID: 36048971191     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200603-440OC     Document Type: Article

References (50)

1. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163:1009-1021.
2. De Cock KM, Chaisson RE. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis 1999;3:457-465.
3. Currie CS, Williams BG, Cheng RC, Dye C. Tuberculosis epidemics driven by HIV: is prevention better than cure? AIDS 2003;17:2501-2508.
4. Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 2005;293:2767-2775.
5. Nunn P, Williams BG, Floyd K, Dye C, Elzinga G, Raviglione M. Tuberculosis control in the era of HIV. Nat Rev Immunol 2005;5:819-826.
6. Bucher HC, Griffith LE, Guyatt GH, Sudre P, Naef M, Sendi P, Battegay M. Isoniazid prophylaxis for tuberculosis in HIV infection: meta-analysis of randomized controlled trials. AIDS 1999;13:501-507.
7. Selwyn PA, Schoenbaum EE, Davenny K, Robertson VJ, Feingold AR, Shulman JF, Mayers MM, Klein RS, Friedland GH, Rogers MF. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;32:545-550.
8. Antonucci G, Girardi E, Raviglione MC, Ippolito C. Risk factors for tuberculosis in HIV-infected persons: a prospective cohort study. The Gruppo Italiano di Studio Tuberculosi e AIDS (GISTA). JAMA 1995;274:143-148.
9. Williams BG, Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 2003;301:1535-1537.
10. Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, Jacobs WR Jr, Hopewell PC. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction fragment length polymorphisms. N Engl J Med 1992;326:321-325.
11. Geng E, Kreiswirth B, Burznyski J, Schluger N. Clinical and radiographic correlates of primary and reactivation tuberculosis: a molecular epidemiology study. JAMA 2005;293:2740-2745.
12. Whalen CC, Nsubuga P, Okwera A, Johnson JL. HoM DL, Michael NL, Mugerwa RD, Ellner JJ. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS 2000;14:1219-1228.
13. Shafer RW, Bloch AB, Larkin C, Vasudavan V, Seligman S, Dehovitz JD, DiFerdinando G, Stoneburner R, Cauthen G. Predictors of survival in HIV-infected tuberculosis patients. AIDS 1996;10:269-272.
14. San Francisco HIV Prevention Planning Council. Apr 2004. 2004 San Francisco HIV Prevention Plan. Centers of Disease Control and Prevention: Cooperative Agreement No. U62CCU923478-01. Available from: San Francisco Department of Public Health (SFDPH) AIDS Office, San Francisco, CA.
15. San Francisco Department of Public Health (SFDPH) AIDS Office. 2004 HIV Consensus Meeting Report. San Francisco, CA: SFDPH AIDS Office.
16. Zolopa AR, Hahn JA, Gorter R, Miranda J, Wlodarczyk D, Petereson J, Pilote L, Moss AR. HIV and tuberculosis infection in San Francisco's homeless adults: prevalence and risk factors in a retrospective sample. JAMA 1994;272:455-461.
17. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2004 Report on the global AIDS epidemic. Geneva, Switzerland: UNAIDS; 2004.
18. DeRiemer K, Kawamura LM, Hopewell PC, Daley CL. Impact of HV on tuberculosis dynamics in San Francisco [abstract 26]. Late Breaker Abstracts Session. 100th International Conference, American Thoracic Society, May 20-25, San Diego, CA; 2005.
19. Jasmer RM, Hahn JA, Small PM, Daley CL, Behr MA, Moss AR, Creasman JM, Schecter GF, Paz EA, Hopewell PC. A molecular epidemiologic analysis of tuberculosis in San Francisco, 1991-1997. Ann Intern Med 1999;130:971-978.
20. van Embden JD, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B, Hermans P, Martin C, McAdam R, Shinnick T, et al. Strain identification of Mycobacterium tuberculosis by DNA finger-printing: recommendations for a standardized methodology. J Clin Microbiol 1993;31:406-409.
21. Woelffer GB, Bradford WZ, Paz A, Small PM. A computer-assisted molecular epidemiologic approach to confronting the reemergence of tuberculosis. Am J Med Sci 1996;311:17-22.
22. Murray M, Alland D. Methodological problems in the molecular epidemiology of tuberculosis. Am J Epidemiol 2002;155:565-571.
23. Chaves F, Yang Z, el Hajj H, Alonso M, Burman WJ, Eisenach KD, Dronda F, Bates JH, Cave MD. Usefulness of the secondary probe pTBN12 in DNA fingerprinting of Mycobacterium tuberculosis. J Clin Microbiol 1996;34:1118-1123.
24. State of California, Department of Finance. Race/ethnic population with age and sex detail, 1990-1999. Sacramento, CA; 2004.
25. State of California, Department of Finance. Race/ethnic population with age and sex detail, 2000-2050. Sacramento, CA; 2004.
26. Small PM, McClenny NB, Singh SP, Schoolnik GK, Tompkins LS, Mickelsen PA. Molecular strain typing of Mycobacterium tuberculosis to confirm cross-contamination in the mycobacteriology laboratory and modification of procedures to minimize occurrence of false-positive cultures. J Clin Microbiol 1993;31:1677-1682.
27. Corbett EL, Bandason T, Cheung YB, Munyati S, Godfrey-Faussett, Hayes R, Churchyard G, Butterworth A, Mason P. Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med 2007;4(e22):e0164-0172.
28. Porco TC, Martin JN, Page-Shafer KA, Cheng A, Charlebois E, Grant RM, Osmond DH. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004;18:81-88.
29. Santoro-Lopes G, Felix de Pinho AM, Harrison LH, Schecter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 202;34:543-546.
30. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long-term incidence and risk factors in a South African cohort. AIDS 2005;19:2109-2116.
31. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002;359:2059-2064.
32. Rieder HL. Methodological issues in the estimation of the tuberculosis problem from tuberculin surveys. Tuber Lung Dis 1995;76:114-121.
33. Fine PE, Bruce J, Ponnighaus JM, Nkhosa P, Harawa A, Vynnycky E. Tuberculin sensitivity: conversions and reversions in a rural African population. Int J Tuberc Lung Dis 1999;3:962-975.
34. Enarson DA. Measuring tuberculosis: lessons from Afghanistan. Int J Tuberc Lung Dis 2004;8:1041-1042.
35. Odhiambo JA, Borgdorff MW, Kiambih FM, Kibuga DK, Kwamanga DO, Ng'ang'a L, Agwanda R, Kalisvaart NA, Misljenovic O, Nagelkerke NJ, et al. Tuberculosis and the HIV epidemic: increasing annual risk of tuberculous infection in Kenya, 1986-1996. Am J Public Health 1999;89:1078-1082.
36. Egwaga SM, Cobelens FG, Muwinge H, Verhage C, Kalisvaart, Borgdorff MW. The impact of the HIV epidemic on tuberculosis transmission in Tanzania. AIDS 2006;20:915-921.
37. Corbett EL, Charalambous S, Moloi VM, Fielding K, Grant AD, Dye C, De Cock K, Hayes RJ, Williams BG, Churchyard GJ. Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med 2004;170:673-679.
38. Wood R, Middelkoop K, Myer L, Grant AD, Whitelaw A, Lawn SD, Kaplan G, Huebner R, McIntyre J, Bekker L-G. Undiagnosed tuberculosis in a community with high HIV prevalence. Am J Respir Crit Care Med 2007;175:87-93.
39. Cruciani M, Malena B, Bosco O, Gatti G, Serpelloni G. The impact of human immunodeficiency virus type 1 on infectiousness of tuberculosis: a meta-analysis. Clin Infect Dis 2001;33:1922-1930.
40. Carvalho AC, DeRiemer K, Nunes ZB, Martins M, Comelli M, Marinoni A, Kritski AL. Transmission of Mycobacterium tuberculosis to contacts of HIV-infected tuberculosis patients. Am J Respir Crit Care Med 2001;164:2166-2171.
41. Glynn JR, Crampin AC, Ngwira BMM, Mwaungulu FD, Mwafulirwa DT, Floyd S, Pönnighaus JM, Warndorff DK, Fine PEM. Trends in tuberculosis and the influence of HIV infection in northern Malawi, 1988-2001. AIDS 2004;18:1459-1463.
42. Crampin AC, Glynn JR, Traore H, Yates MD, Mwaungulu L, Mwenebabu M, Steven D, Chaguluka SD, Floyd S, Drobniewski F, et al. Tuberculosis transmission attributable to close contacts and HIV status, Malawi. Emerg Infect Dis 2006;12:729-735.
43. Suggaravetsiri P, Yani H, Chongsuvivatwong V, Naimpasan O, Akaresewi P. Integrated counseling and screening for tuberculosis and HIV among household contacts of tuberculosis patients in an endemic area of HIV infection: Chiang Rai, Thailand. Int J Tuberc Lung Dis 2003;7(12, Suppl 3):S424-S431.
44. Reichler MR, Bur S, Reeves R, Mangura B, Thompson V, Ford J, Castro KG. Results of testing for human immunodeficiency virus infection among recent contacts of infectious cases in the United States. Int J Tuberc Lung Dis 2003;7(12, Suppl 3):S471-S478.
45. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005;191:150-158.
46. Porco TC, Small PM, Blower SM. Amplification dynamics: predicting the effect of HIV on tuberculosis outbreaks. J Acquir Immune Defic Syndr 2001;28:437-444.
47. Godfrey-Faussett P, Mahler D, Mukadi YD, Nunn P, Perriëns J, Raviglione M. How human immunodeficiency virus voluntary testing can contribute to tuberculosis control. Bull World Health Organ 2002;80:939-945.
48. American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of America. Controlling tuberculosis in the United States: recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. Am J Respir Crit Care Med 2005;172:1169-1227.
49. Paltiel DA, Weinstein MC, Kimmel AD, Seage GR III, Losine E, Zhang H, Freedberg KA, Walensky RP. Expanding HIV screening in the United States: an analysis of cost-effectiveness. N Engl J Med 2005;352:586-595.
50. Sanders GD, Gayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, Douglass LR, Lazzeroni LC, Holodniy M, Owens DK. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005;352:570-585.